Page 87 - Portuguese Journal - SPORL - Vol 61. Nº1

Evaluated Study or Intervention Group Placebo Group Mean Difference;
Parameter Subgroup Mean, IV, Random,
Mean Standard Total Mean Standard Total 95% CI
Deviation Participants Deviation Participants
OMALIZUMAB
POLYP 1 (b,c) -24.7 17.06 72 -8.58 16.9 66 -16.12 [-21.79,-10.45]
POLYP 2 (b,c) -21.59 17.72 62 -6.55 17.66 65 -15.04 [-21.20,-8.88]
SNOT-22 Total (95% CI) 134 131 -15.62 [-19.79,-11.45]

Heterogeneity: Tau =0.00; Chi =0.06, df=1 (P=0,.80); I =0%
2
2
2
Test for overall effect: Z=7.34 (P<0,.00001)
Gevaert 2013 (b,d) -2.67 1.55 15 -0.12 0.03 8 -2.55 [-3.33,-1.77]
POLYP 1 (b,c) -1.08 1.36 72 0.06 1.3 66 -1.14 [-1.58,-0.70]
POLYP 2 (b,c) -0.9 1.34 62 -0.31 1.29 65 -0.59 [-1.05,-0.13]
NPS
Total (95% CI) 149 139 -1.37 [-2.30,-0.44]
Heterogeneity: Tau =0.59; Chi =17.91, df=2 (P=0,.0001); I =89%
2
2
2
Test for overall effect: Z=2.89 (P=0,.004)
Gevaert 2013 (d) -13.6 4.33 15 18.3 6.32 8 -4.70 [-9.60,0.20]
Lund Mackay Total (95% CI) 15 8 -4.70 [-9.60,0.20]
Score
Heterogeneity: Not Applicable
Test for overall effect: Z=1.88 (P=0,.06)
MEPOLIZUMAB
Mean minimum square
Bachert 2017 (e) 27.19 22.12 54 40.4 24.59 51 -13.21 [-22.17,-4.25]
Subtotal (95% CI) 54 51 -13.21 [-22.17,-4.25]
Heterogeneity: Not Applicable
Test for overall effect: Z=2.89 (P=0,.004)
Mean
SNOT-22 SYNAPSE (b) -29.4 24.67 206 -15.7 23.93 201 -13.70 [-18.42,-8.98]
Subtotal (95% CI) 206 201 -13.70 [-18.42,-8.98]
Heterogeneity: Not Applicable
Test for overall effect: Z=5.69 (P<0,.00001)
Total (95% CI) 260 252 -13.59 [-17.77,-9.42]
Heterogeneity: Tau =0.00; Chi =0.01, df=1 (P=0,.92); I =0%
2
2
2
Test for overall effect: Z=6.38 (P<0,.00001)
Test for differences between subgroups: Chi =0.01, df=1 (P=0,.92); I =0%
2
2
Gevaert 2011 (b) -1.3 1.72 20 0 0.94 10 -1.30 [-2.25,-0.35]
SYNAPSE (b) -0.9 1.9 206 -0.1 1.46 201 -0.80 [-1.13,-0.47]
NPS Total (95% CI) 226 211 -0.85 [-1.16,-0.54]
Heterogeneity: Tau =0.00; Chi =0.95, df=1 (P=0,.33); I =0%
2
2
2
Test for overall effect: Z=5.38 (P<0,.00001)

Volume 61 . Nº1 . March 2023 87